MedPath

Registry of Patients Living with Type 1 Diabetes

Recruiting
Conditions
Type 1 Diabetes Mellitus
Interventions
Other: Online questionnaire - Phase 1
Other: Online questionnaire - Phase 2
Other: Continuous glucose monitor
Other: Online questionnaire - Phase 3
Other: Food questionnaire
Other: Pedometer
Other: Waist circumference
Other: Blood and urine tests
Other: List of medications
Registration Number
NCT03720197
Lead Sponsor
Institut de Recherches Cliniques de Montreal
Brief Summary

A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes living in Canada will be established. The objective of this registry will be to measure the frequency and the severity of episodes of hypoglycemia. Participants will be invited to answer questionnaires about the frequency of their hypoglycemic episodes, their fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin therapy, nutrition, exercise, etc.), etc.

Participation to the registry is divided in 3 phases. The first phase is mandatory for all participants. Phases 2 and 3 are optional.

Detailed Description

The objective of phase 1 is to draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications. It takes about 10 minutes to answer the questionnaire. If the participant uses a continuous glucose monitor and agrees, the participant is invited to send the latest report of the continuous glucose monitor.

The objective of phase 2 is to characterize the causes, experience and consequences of hypoglycemia. Phase 2 also involves, if the participant accepts and live in the province of Quebec or Alberta, to provide the research team with their latest blood and urine tests as well as their list of medications.

The objective of phase 3 is to collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia. Phase 3 also involves, if the participant agrees, answering a food questionnaire, wearing a step counter, measuring waist circumference

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
6000
Inclusion Criteria
  • Diagnosis of type 1 diabetes
  • Living in Canada
Exclusion Criteria
  • Type 2 diabetes
  • Gestational diabetes

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Participants aged 14 years old and olderOnline questionnaire - Phase 2-
Participants aged 14 years old and olderList of medications-
Participants aged 14 years old and olderOnline questionnaire - Phase 1-
Participants aged less than 14 years oldContinuous glucose monitor-
Participants aged 14 years old and olderFood questionnaire-
Participants aged 14 years old and olderWaist circumference-
Participants aged 14 years old and olderContinuous glucose monitor-
Participants aged less than 14 years oldOnline questionnaire - Phase 1-
Participants aged 14 years old and olderOnline questionnaire - Phase 3-
Participants aged 14 years old and olderPedometer-
Participants aged 14 years old and olderBlood and urine tests-
Primary Outcome Measures
NameTimeMethod
Number of non-severe hypoglycemic episodes12 months

Participants will be asked to report the number of non-severe hypoglycemic episodes in the last 12 months in a questionnaire designed by the investigators. The definition of non-severe hypoglycemia is a blood sugar below 3.0 mmol/L that the participant was able to treat himself

Secondary Outcome Measures
NameTimeMethod
Number of steps14 days

The number of steps will be measured by a pedometer

Number of severe hypoglycemic episodes12 months

Participants will be asked to report the number of severe hypoglycemic episodes in the last 12 months in a questionnaire designed by the investigators. The definition of severe hypoglycemia is low blood sugar levels requiring help from another person or use of glucagon or hospitalization or loss of consciousness.

Diabetes distress1 month

Diabetes distress will be assessed by the Diabetes Distress Scale.

Physical activity1 week

Physical activity will be assessed by the International Physical Activity Questionnaire.

Fear of hypoglycemia6 months

Fear of hypoglycemia will be assessed by the Hypoglycemia Fear Survey II.

Sleep habits1 month

Sleep habits will be assessed by the Pittsburgh Sleep Quality Index

Depression2 weeks

Depression will be assessed by the Patient Health Questionnaire (PHQ-9)

Medical follow-up for diabetes12 months

Participants will be asked to report in a questionnaire designed by the investigators how many times in the last 12 months they have seen a health care professionals (family doctor, medical specialist, nurse, nutritionnist, kinesiologist, psychologist, pharmacist, social worker).

Insulin doses3 days

Participants will be asked to report in a questionnaire designed by the investigators their insulin doses of the last 3 days (basal insulin and insulin given at mealtime).

Trial Locations

Locations (7)

Alberta Diabetes Institute

🇨🇦

Edmonton, Alberta, Canada

Institut de recherches cliniques de Montréal

🇨🇦

Montreal, Quebec, Canada

Centre Hospitalier de l'Université de Montréal

🇨🇦

Montreal, Quebec, Canada

Centre Hospitalier Universitaire Sainte-Justine

🇨🇦

Montreal, Quebec, Canada

McGill University Health Centre

🇨🇦

Montreal, Quebec, Canada

Centre hospitalier universitaire de Sherbrooke

🇨🇦

Sherbrooke, Quebec, Canada

Centre Hospitalier Universitaire de Québec-Université Laval

🇨🇦

Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath